CAR-T Cell Therapy Shows EFS Benefit in Pediatric Leukemia Subset

Treatment with bicistronic CD19/CD22 CAR-T cell therapy has shown event-free survival improvements in children with relapsed or refractory B-ALL.

Read more: https://www.curetoday.com/view/car-t-cell-therapy-shows-efs-benefit-in-pediatric-leukemia-subset